35636-10-3

Basic information

• Product Name: 1-BENZYL-4-CHLORO-5-AZAINDOLE
• Synonyms: 1-BENZYL-4-CHLORO-5-AZAINDOLE;1-benzyl-4-chloro-1H-pyrrolo[3,2-c]pyridine
• CAS NO: 35636-10-3
• Molecular Formula: C₁₄H₁₁ClN₂
• Molecular Weight: 242.7035
• Mol File: 35636-10-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 418.614 °C at 760 mmHg
• Flash Point: 206.971 °C
• Appearance: /
• Density: 1.23 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-BENZYL-4-CHLORO-5-AZAINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-CHLORO-5-AZAINDOLE(35636-10-3)
• EPA Substance Registry System: 1-BENZYL-4-CHLORO-5-AZAINDOLE(35636-10-3)

Safety Data

• Hazardous Substances Data: 35636-10-3(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-chloro-5-azaindole is a chemical compound with the molecular formula C14H11ClN2. It is a heterocyclic organic compound that contains a benzyl group and a chlorine atom attached to a five-membered nitrogen-containing ring. 1-Benzyl-4-chloro-5-azaindole is often used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has been studied for its potential biological activities, including its antiviral and antitumor properties. Additionally, 1-Benzyl-4-chloro-5-azaindole has also been investigated for its potential use as a fluorescent probe in analytical and biological applications. Overall, this compound has diverse potential applications and is a valuable molecule in chemical and biological research.

Upstream product

• 100-39-0 benzyl bromide 
• 60290-21-3 4-chloro-1H-pyrrolo-[3,2-c]-pyridine 
• 26956-47-8 1-benzyl-4,5-dihydro-4-oxopyrrolo<3,2-c>pyridine 

Downstream Products

• 102998-41-4 benzyl-1 (α-methoxy-4' phenyl α-hydroxy)ethyl-2 chloro-4 pyrrolo<3,2-c>pyridine 
• 637000-19-2 tert-butyl 4-(1-benzyl-1H-pyrrolo[3,2-c]pyridin-4-yl)piperazine-1-carboxylate 
• 106689-68-3 (E)-3-(1-Benzyl-4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)-but-2-enoic acid ethyl ester 
• 106689-70-7 acide β-(benzyl-1 chloro-4-1H-pyrrolo<3,2-c>pyridyl-2)crotonique 
• 106689-63-8 benzyl-1 acetyl-2 chloro-4-1H-pyrrolo<3,2-c>pyridine 
• 102998-58-3 benzyl-1 (α-p-methoxyphenyl)ethyl-2 formyl-3 chloro-4 pyrrolo<3,2-c>pyridine 
• 102998-55-0 benzyl-1 (α-methoxy-4' phenyl)ethyl-2 chloro-4 pyrrolo<3,2-c>pyridine 
• 102998-52-7 1-Benzyl-2-[1-(4-methoxy-phenyl)-ethyl]-1,5-dihydro-pyrrolo[3,2-c]pyridin-4-one 
• 102998-49-2 1-Benzyl-2-[1-(4-methoxy-phenyl)-vinyl]-1,5-dihydro-pyrrolo[3,2-c]pyridin-4-one 
• 102998-48-1 1-benzyl-4-chloro-2-(1-(4-methoxyphenyl)vinyl)-1H-pyrrolo[3,2-c]pyridine 
• 35801-12-8 benzyl-(1-benzyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-amine 
• 106689-62-7 benzyl-1 (α-hydroxyethyl)-2 chloro-4-1H-pyrrolo<3,2-c>pyridine 

Relevant articles and documents

Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3and 5-HT6Receptor Antagonist with Antipsychotic and Procognitive Properties

In line with recent clinical trials demonstrating that ondansetron, a 5-HT3receptor (5-HT3R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT6receptor (5-HT6R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists. We identified the first-in-class compoundFPPQ, which behaves as a 5-HT3R antagonist and a neutral antagonist 5-HT6R of the Gs pathway.FPPQshows selectivity over 87 targets and decent brain penetration. Likewise,FPPQinhibits phencyclidine (PCP)-induced hyperactivity and displays procognitive properties in the novel object recognition task. In contrast toFPPQ, neither 5-HT6R inverse agonist SB399885 nor neutral 5-HT6R antagonist CPPQ reversed (PCP)-induced hyperactivity. Thus, combination of 5-HT3R antagonism and 5-HT6R antagonism, exemplified byFPPQ, contributes to alleviating the positive-like symptoms. Present findings reveal critical structural features useful in a rational polypharmacological approach to target 5-HT3/5-HT6receptors and encourage further studies on dual-acting 5-HT3/5-HT6R antagonists for the treatment of psychiatric disorders.